title: Modifying mesoporous silica nanoparticles to avoid the metabolic deactivation of 6-mercaptopurine and methotrexate in combinatorial chemotherapy.
abstract: Mesoporous silica nanoparticles with amino and thiol groups (MSNSN) were prepared and covalently modified with methotrexate and 6-mercaptopurine to form 6-MP-MSNSN-MTX. In the presence of DTT, 6-MP-MSNSN-MTX gradually releases 6-MP. In rat plasma, 6-MP-MSNSN-MTX effectively inhibits the metabolic deactivation of 6-MP and MTX. 6-MP-MSNSN-MTX could be an agent for long-acting chemotherapy.
authors.affiliation: College of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China.
authors.forename: Wenjing
authors.initials: W
authors.lastname: Wang
authors.forename: Chenjie
authors.initials: C
authors.lastname: Fang
authors.forename: Xiaozhu
authors.initials: X
authors.lastname: Wang
authors.forename: Yuxi
authors.initials: Y
authors.lastname: Chen
authors.forename: Yaonan
authors.initials: Y
authors.lastname: Wang
authors.forename: Wei
authors.initials: W
authors.lastname: Feng
authors.forename: Chunhua
authors.initials: C
authors.lastname: Yan
authors.forename: Ming
authors.initials: M
authors.lastname: Zhao
authors.forename: Shiqi
authors.initials: S
authors.lastname: Peng
mesh_terms: D049109:Cell Proliferation / Q000187:drug effects; D004229:Dithiothreitol / Q000737:chemistry; D004705:Endocytosis; D006801:Humans; D020014:K562 Cells; D015122:Mercaptopurine / Q000378:metabolism / Q000627:therapeutic use / Q000633:toxicity; D053768:Metal Nanoparticles / Q000737:chemistry*; D008727:Methotrexate / Q000378:metabolism / Q000627:therapeutic use / Q000633:toxicity; D009369:Neoplasms / Q000188:drug therapy; D016062:Porosity; D012822:Silicon Dioxide / Q000737:chemistry*; D013499:Surface Properties
chemical_list: D012822:Silicon Dioxide; D015122:Mercaptopurine; D004229:Dithiothreitol; D008727:Methotrexate